|
The aim of the present study was to detect osteopontin (OPN) and vascular endothelial growth factor (VEGF) in acute leukemia (AL) grouped in different stages of serum content analysis in untreated patients OPN, VEGF peripheral blood white blood cell (WBC) count, the relationship between the original bone marrow cells, lactate dehydrogenase (LDH), β2-microglobulin (β2-MG), and OPN, VEGF both, and then investigate serum OPN, VEGF, and AL occur, the development of the relationship, and anti-angiogenesis therapy provide a theoretical basis AL. Method of enzyme-linked immunosorbent assay (ELISA) determination of the initial issuance of the untreated group, 25 cases, 19 cases of complete remission (CR) group, no remission (NR) group of 14 cases, 11 cases of recurrent group of 69 patients with AL serum OPN VEGF content, compared with a control group of 20 patients. Results 1 found by measuring the level of each group in the AL serum OPN OPN in untreated group, CR group, NR group, the recurrence group and normal control group, serum OPN onset untreated group were significantly higher than the normal control group, the difference was statistically significant (P lt; 0.01); CR serum OPN content was increased in the untreated group was significantly decreased compared with the normal control group, the difference was not statistically significance (P gt; 0.05); NR group, relapse The serum OPN content was significantly higher than normal control group and CR group, the differences were statistically significant (P lt; 0.01). By measuring the level of each group in the AL serum VEGF, VEGF in untreated group, CR group, NR group, the relapse group, the control group, serum VEGF levels of the initial issuance of the untreated group was significantly higher than the normal control group , the difference was statistically significant (P lt; 0.01); CR serum VEGF content was increased in the untreated group was significantly decreased compared with the normal control group, the difference was not statistically significance (P gt; 0.05); NR group, relapse group Serum VEGF were significantly higher than the normal control group and CR group, the differences were statistically significant (P lt; 0.01). AL serum OPN different types of analysis in untreated group, the levels of VEGF, OPN content of the serum of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) group, the difference was not statistically significant ( P gt; 0.05); the AML set of serum VEGF levels and ALL group, the difference was not statistically significance (P gt; 0.05). ALL serum OPN different types of analysis in untreated group, the levels of VEGF, found that the the serum OPN content of Ph chromosome-positive (Ph) group was significantly higher than the Ph chromosome negative (Ph-) group, the difference was statistically significant ( the Ph serum VEGF levels and the Ph-group comparison, the difference was not statistically significance (P gt; 0.05) P lt; 0.05); Onset the untreated serum OPN content and related clinical factors analysis serum OPN content and bone marrow blasts percentage, β2-MG is not related (r values ??were 0.03,0.36, P gt; 0.05), and peripheral WBC count , LDH were positively correlated (r values ??were 0.44,0.45, P lt; 0.05). Onset untreated serum VEGF levels in clinically relevant factors not related to analysis of serum VEGF levels in bone marrow blasts percentage (r = 0.02, P gt; 0.05), and peripheral WBC count, LDH, β2-MG There was a positive correlation (r values ??were 0.43,0.52,0.47, P lt; 0.05). Onset untreated serum OPN and VEGF content correlation analysis between the two was a positive correlation (r = 0.42, P lt; 0.05). Conclusion OPN, VEGF, and AL occurred, the development is closely related to the serum content related to the condition of AL. OPN, VEGF as AL disease diagnosis, efficacy, to understand the disease, prognostic indicator. OPN, VEGF was positively correlated with each other to promote expression of OPN and VEGF mechanism, synergy in angiogenesis. BCR-ABL fusion gene can up-regulate the expression of OPN. Therefore, the anti-OPN and VEGF-targeted anti-tumor angiogenesis therapy, is expected to become the new method of treatment of the AL.
|